Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
It has been reported that DACT1 functions in embryonic development and tumorigenesis.
|
29136762 |
2018 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/β-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in breast tumorigenesis remains unclear.
|
23497530 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified DACT1 as a negative regulator in type I EOC, protecting against malignant expansion by inhibiting canonical Wnt signalling and cis-platinum resistance by regulating autophagy.
|
28839145 |
2017 |
Carcinoma, Transitional Cell
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas.
|
23244112 |
2012 |
Cataract
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL cell lines and samples from patients with ALL.
|
17148581 |
2007 |
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
DACT1 has been shown to participate in the development of many types of tumors; however, its role and precise molecular mechanisms in leukemia are unclear.
|
29037126 |
2017 |
Clinodactyly of the 5th finger
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Clinodactyly of toe
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Coloboma of iris
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Coloboma of the Retina
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we present evidence that DACT1 is an important positive regulator in colon cancer through regulating the stability and sublocation of β-catenin.
|
22470507 |
2012 |
Colorectal Carcinoma
|
0.510 |
Biomarker
|
disease |
BEFREE |
Here we identify DACT3, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/beta-catenin signaling that is transcriptionally repressed in colorectal cancer.
|
18538736 |
2008 |
Colorectal Carcinoma
|
0.510 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Colorectal Carcinoma
|
0.510 |
Biomarker
|
disease |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Colorectal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
DACT1 is a member of the Wnt-signaling pathway, and mice homozygous for null alleles display multiple congenital anomalies including absent anus with blind-ending colon and genitourinary malformations.
|
28054444 |
2017 |
Congenital coloboma of iris
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital diaphragmatic hernia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital ear anomaly NOS (disorder)
|
0.110 |
Biomarker
|
group |
BEFREE |
A heterozygous nonsense variant was identified in dapper, antagonist of beta-catenin, 1 (DACT1) via whole-exome sequencing in family members with imperforate anus, structural renal abnormalities, genitourinary anomalies, and/or ear anomalies.
|
28054444 |
2017 |
Congenital ear anomaly NOS (disorder)
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
Congenital hypoplasia of kidney
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital hypoplasia of penis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital malformation syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
DACT1 is a member of the Wnt-signaling pathway, and mice homozygous for null alleles display multiple congenital anomalies including absent anus with blind-ending colon and genitourinary malformations.
|
28054444 |
2017 |
Congenital omphalocele
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|